Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
0 hedge funds and large institutions have $0 invested in Five Prime Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 147 closing their positions.
89.41% less ownership
Funds ownership: 89.41% → 0% (-89%)
100% less funds holding
Funds holding: 147 → 0 (-147)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $1.56B
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 147
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$239M |
| 2 |
BlackRock
New York
|
-$116M |
| 3 |
Rock Springs Capital Management
Baltimore,
Maryland
|
-$100M |
| 4 |
Magnetar Financial
Evanston,
Illinois
|
-$90.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$81.7M |
FPRX Hedge Fund Activity: Q2 2021 in Review
0 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2021, worth a combined $0 — down 100% from $1.56B a quarter earlier.
Sellers outnumbered buyers: 147 funds closed out of FPRX and 0 opened new positions — a net loss of 147 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BVF Inc, exiting entirely with an estimated $239M sold.
- 0 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2021, down from 147 in Q1 2021.
- Funds reported $0 of Five Prime Therapeutics, Inc. stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2021 and 147 closed out, a net change of -147 holders.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2021 was BVF Inc, an estimated $239M sold.
Based on aggregated 13F filings for Q2 2021.